Reframe Daily: Gene therapy helps deaf kids hear; 2 stroke-care wins; kidney pill works; new pancreatic-cancer combo

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: 

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A one-time gene therapy let many deaf children hear; stroke patients did better when doctors used full anesthesia and added a small dose of clot medicine after opening the artery; an oral pill protected kidneys in a rare disease; and a new drug mix beat standard chemo for pancreatic cancer.

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomized, double-blind, placebo-controlled phase 3 study

Market readiness: 🙂🙂🙂🙂🙂 (already FDA-approved in the U.S. for C3G; this paper adds peer-reviewed phase 3 evidence behind current use). 

Good news: A one-time inner-ear gene therapy let many deaf children hear again—some reached normal hearing. That’s life-changing for speech and learning.

DB-OTO Gene Therapy for Inherited Deafness

Market readiness: 🙂🙂🙂🙂 (phase 1/2 “registrational” data with strong results; Regeneron says it plans an FDA filing this year, but it’s not yet approved). 

Good news: After successful clot retrieval for stroke, adding a small dose of clot-buster directly in the artery helped more people get back to normal function.

Intra-Arterial Alteplase After Successful Endovascular Reperfusion in Acute Stroke: The PEARL Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂 (alteplase is already widely available in U.S. hospitals; this RCT supports a procedural add-on that guidelines could adopt next). 

Good news: For emergency stroke treatment, using full general anesthesia (instead of sedation) during thrombectomy led to better recovery and higher success opening the blocked artery.

Sedation vs General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke (SEGA): Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂 (both anesthesia approaches are standard; this trial favors GA and could change protocols quickly without new approvals). 

Good news: A new combo—chemotherapy plus an immune drug and a targeted pill—shrank pancreatic tumors more often and delayed growth compared with standard chemo in a randomized study.

First-line treatment with chemotherapy, surufatinib, and camrelizumab for advanced pancreatic ductal adenocarcinoma: phase Ib/II randomized study

Market readiness: 🙂🙂 (early-phase randomized data from China; promising but needs larger, confirmatory trials before U.S. use). 

Thank you for taking the time to take care of yourself and your loved ones.